Daniel Kedar
Papers
1
Total Citations
37
H-Index
1
About
Daniel Kedar is a pioneering researcher in the field of theranostics and urologic oncology, with a focused expertise in the application of radioligand therapy for prostate cancer. His most significant contribution to date is his leadership in a groundbreaking single-arm Phase 1 trial investigating neoadjuvant 177Lu-PSMA-I&T radionuclide treatment in high-risk prostate cancer patients prior to radical prostatectomy. This work, published in 2022 and already garnering 37 citations, represents a critical step toward integrating targeted molecular radiotherapy into the surgical management of aggressive disease, potentially improving outcomes by eradicating micrometastases before surgery. Kedar’s research sits at the intersection of nuclear medicine and surgical oncology, demonstrating how PSMA-targeted therapies can be safely and effectively administered in a neoadjuvant setting. His findings have opened new avenues for clinical trials and sparked interest in combining radionuclide treatment with standard surgical protocols. For students and researchers, Kedar’s work exemplifies the translational power of theranostics—using diagnostic imaging to guide precise, personalized therapy—and highlights the evolving landscape of prostate cancer treatment where multidisciplinary approaches are key.
Research Focus
Key Achievements
Top Papers
- 1